When prostate cancer markers become unreliable: the PCPT dilemma.
Gomella
Leonard G
LG
D014408:Biomarkers, Tumor / Q000032:analysis* / Q000592:standards*; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D018120:Finasteride / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009367:Neoplasm Staging / Q000379:methods*; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000473:pathology*; D015203:Reproducibility of Results
D014408:Biomarkers, Tumor; D004791:Enzyme Inhibitors; D018120:Finasteride; D017430:Prostate-Specific Antigen